Elena Curto Sanchez
@santpau.cat
Scopus Publications
Scopus Publications
Diana Betancor, Blanca Barroso, Marcela Valverde-Monge, Alicia Gomez-Lopez, Joaquin Sastre, José María Olaguibel, José Manuel Rodrigo-Muñoz, Maria Jose Alvarez Puebla, Ebymar Arismendi, Irina Bobolea,et al.
Elsevier BV
Esther Palones, Elena Curto, Vicente Plaza, Lidia Gonzalez-Quereda, Alba Segarra-Casas, Luis Querol, Federico Bertoletti, María José Rodriguez, Pía Gallano, and Astrid Crespo-Lessmann
Springer Science and Business Media LLC
AbstractCerebellar ataxia with neuropathy and bilateral vestibular areflexia syndrome (CANVAS) is an hereditary autosomal recessive disease. Recent studies propose including chronic cough (CC) as a symptom of CANVAS. For 10 patients with CANVAS as genetically confirmed by biallelic expansion of the AAGG repeat motif (AAGGGexp) in intron 2 of replication factor C subunit 1 (RFC1), our aim was, as a multidisciplinary team, to describe clinical and functional characteristics and possible causes of CC following European Respiratory Society (ERS) recommendations, and to evaluate CC impact on quality of life (QoL) using self-administered questionnaires (Cough Severity Diary, Leicester Cough Questionnaire, Discrete Emotions Questionnaire, and EQ-5D-5L). In all 10 patients, the CC was a dry cough that developed several years prior to the neurological symptoms (mean 14.2 years); 7 patients had symptoms compatible with gastroesophageal reflux (GER), 5 with pathological GER diagnosed by 24-h esophageal pH testing, and 6 patients had impaired esophageal motility diagnosed by high-resolution esophageal manometry, most frequently ineffective peristalsis. Although further studies are required for confirmation, we conclude that CC may be a characteristic prodrome of CANVAS and may be related to GER and esophageal disorders. Furthermore, CC affects patients’ QoL, especially in the psychosocial sphere.
Esther Palones, Elena Curto, Anna Pelegrí, Marina Arilla, Ingrid Solanes, and Astrid Crespo-Lessmann
Elsevier BV
Christian Romero-Mesones, Maria-Jesus Cruz, Isam Alobid, Blanca Barroso, Ebymar Arismendi, Pilar Barranco, Diana Betancor, Irina Bobolea, Blanca Cárdaba, Elena Curto,et al.
Elsevier BV
Diana Betancor, Carlos Villalobos-Vilda, José María Olaguibel, José Manuel Rodrigo-Muñoz, María Jose Alvarez Puebla, Ebymar Arismendi, Pilar Barranco, Blanca Barroso, Irina Bobolea, Blanca Cárdaba,et al.
Elsevier BV
Marcos Matabuena, Francisco Javier Salgado, Juan José Nieto-Fontarigo, María J. Álvarez-Puebla, Ebymar Arismendi, Pilar Barranco, Irina Bobolea, María L. Caballero, José Antonio Cañas, Blanca Cárdaba,et al.
Elsevier BV
Noe Garin, Borja Zarate-Tamames, Laura Gras-Martin, Raimon Milà, Astrid Crespo-Lessmann, Elena Curto, Marta Hernandez, Conxita Mestres, and Vicente Plaza
MDPI AG
We conducted a systematic review and meta-analysis to gain insight into the characteristics and clinical impact of electronic monitoring devices of inhalers (EMDs) and their clinical interventions in adult patients with asthma or COPD. The search included PubMed, Web of Science, Cochrane, Scopus and Embase databases, as well as official EMDs websites. We found eight observational studies and ten clinical trials, assessing a wide range of clinical outcomes. Results from the meta-analysis on adherence to inhalers in a period over three months were favourable in the EMD group (fixed effects model: SMD: 0.36 [0.25–0.48]; random effects model SMD: 0.41 [0.22–0.60]). An exploratory meta-analysis found an improvement in ACT score (fixed effect model SMD: 0.25 [0.11–0.39]; random effects model: SMD: 0.47 [−0.14–1.08]). Other clinical outcomes showed mixed results in the descriptive analyses. The findings of this review highlight the benefits of EMDs in the optimization of adherence to inhaled therapy as well as the potential interest in other clinical outcomes.
B Barroso, M Valverde-Monge, I Alobid, JM Olaguibel, MJ Rial, S Quirce, E Arismendi, P Barranco, D Betancor, I Bobolea,et al.
Esmon Publicidad, SA
Astrid Crespo-Lessmann, Elena Curto, Eder Freddy Mateus Medina, Esther Palones, Alicia Belda Soler, Soraya Sánchez Maza, Lorena Soto-Retes, and Vicente Plaza
Informa UK Limited
[This corrects the article DOI: 10.2147/JAA.S389402.].
C Betancor, JM Olaguibel, JM Rodrigo-Muñoz, MJ Alvarez Puebla, E Arismendi, P Barranco, B Barroso, I Bobolea, B Cárdaba, MJ Cruz,et al.
Esmon Publicidad, SA
Servicio de Alergología, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain Servicio de Alergología, Hospital Universitario de Navarra, Pamplona, Navarra, Spain CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain Servicio de Inmunología, Instituto de Investigación Sanitaria Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain Allergy Unit & Severe Asthma Unit, Pneumonology and Allergy Department, Hospital Clínic; IDIBAPS; Universitat de Barcelona, Barcelona, Spain Servicio de Alergia, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain Departamento de Biología Celular, Fisiología e Inmunología, Universitat Autónoma de Barcelona, Barcelona, Spain Servicio de Neumología y Alergia, Hospital de la Santa Creu i Sant Pau, Instituto de Investigación Biomédica Sant Pau (IIB Sant Pau), Universidad Autónoma de Barcelona; Departamento de Medicina, Barcelona, Spain Servicio de Neumología, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, La Coruña, Spain Servicio de Neumología, Hospital Germans Trias i Pujol, Institut d’Investigació Germans Trias i Pujol, Badalona, Barcelona, Universitat Autònoma de Barcelona, Spain Rhinology Unit & Smell Clinic, ENT Department; Clinical and Experimental Respiratory Immunoallergy (IDIBAPS); Universitat de Barcelona. Barcelona, Spain Servicio de Neumología, Hospital Vall d’Hebron, Barcelona, Spain Servicio de Alergología, Complexo Hospitalario Universitario A Coruña, A Coruña, Spain
J Domínguez-Ortega, JA Luna-Porta, JM Olaguibel, P Barranco, E Arismendi, B Barroso, D Betancor, I Bobolea, ML Caballero, B Cárdaba,et al.
Esmon Publicidad, SA
Introduction: Comorbidities can influence asthma control and promote asthma exacerbations (AEs). However, the impact of multimorbidity in AEs, assessed based on long-term follow-up of patients with asthma of different degrees of severity, has received little attention in real-life conditions. Objective: To describe the epidemiological and clinical characteristics and predictors of AEs in patients who had presented at least 1 AE in the previous year in the MEchanism of Genesis and Evolution of Asthma (MEGA) cohort. Methods: The work-up included a detailed clinical examination, pulmonary function testing, fractional exhaled nitric oxide (FeNO), blood counts, induced sputum, skin prick-tests, asthma questionnaires, and assessment of multimorbidity. The number of moderate-severe AEs in the preceding year was registered for each patient. Results: The study population comprised 486 patients with asthma (23.7% mild, 35% moderate, 41.3% severe). Disease remained uncontrolled in 41.9%, and 47.3% presented ≥1 moderate-severe AE, with a mean (SD) annual exacerbation rate of 0.47 (0.91) vs 2.11 (2.82) in mild and severe asthma, respectively. Comorbidity was detected in 56.4% (66.6% among those with severe asthma). Bronchiectasis, chronic rhinosinusitis with nasal polyps, atopy, psychiatric illnesses, hyperlipidemia, and hypertension were significantly associated with AEs. No associations were found for FeNO, blood eosinophils, or total serum IgE. Sputum eosinophilia and a high-T2 inflammatory pattern were significantly associated with AEs. Multivariable regression analysis showed a significant association with asthma severity, uncontrolled disease, and low prebronchodilator FEV1/FVC. Conclusions: Our study revealed a high frequency of AE in the MEGA cohort. This was strongly associated with multimorbidity, asthma severity, poor asthma control, airflow obstruction, higher sputum eosinophils, and a very high-T2 inflammatory pattern.
B Barroso, M Valverde-Monge, I Alobid, JM Olaguibel, MJ Rial, S Quirce, E Arismendi, P Barranco, D Betancor, I Bobolea,et al.
Esmon Publicidad, SA
Esther Palones, Elena Curto, Anna Pelegrí, Marina Arilla, Ingrid Solanes, and Astrid Crespo-Lessmann
Elsevier BV
Astrid Crespo-Lessmann, Elena Curto, Eder Freddy Mateus Medina, Esther Palones, Alicia Belda Soler, Soraya Sánchez Maza, Lorena Soto-Retes, and Vicente Plaza
Informa UK Limited
Purpose The objectives of this study were, for patients attending a specialist asthma clinic at a tertiary care hospital, to determine, from sputum induction (SI), proportions of bronchial inflammatory phenotypes, demographic, clinical and functional characteristics of each phenotype, and the most accessible non-invasive inflammatory marker that best discriminates between phenotypes. Patients and Methods Included were 96 patients with asthma, attending a specialist asthma clinic at a tertiary care hospital, who underwent testing as follows: SI, spirometry, fractional exhaled nitric oxide (FeNO), blood eosinophilia, total immunoglobulin E (IgE), and a skin prick test. Results SI phenotypes were 46.9% eosinophilic, 33.3% paucigranulocytic, 15.6% neutrophilic, and 4.2% mixed. No significantly different clinical or functional characteristics were observed between the phenotypes. A positive correlation was observed between SI eosinophilia and both emergency visits in the last 12 months (p = 0.041; r = 0.214) and FeNO values (p = 0.000; r = 0.368). Blood eosinophilia correlated with SI eosinophilia (p = 0.001; r = 0.362) and was the best predictor of bronchial eosinophilia, followed by FeNO, and total blood IgE (area under the receiver operating characteristic curve (AUC-ROC) 72%, 65%, and 53%, respectively), although precision was only fair. Conclusion In consultations for severe asthma, the most frequent phenotype was eosinophilic. Peripheral blood eosinophilia is a reliable marker for discriminating between different bronchial inflammatory phenotypes, is useful in enabling doctors to select a suitable biologic treatment and so prevent asthma exacerbation, and is a better predictor of bronchial eosinophilia than FeNO and IgE values.
Elena Curto, Éder F. Mateus-Medina, Astrid Crespo-Lessmann, Rubén Osuna-Gómez, Cristina Ujaldón-Miró, Alba García-Moral, Paula Galván-Blasco, Lorena Soto-Retes, David Ramos-Barbón, and Vicente Plaza
MDPI AG
Two subsets of eosinophils have been described: resident eosinophils with homeostatic functions (rEOS) in healthy subjects and in patients with nonallergic eosinophilic asthma, and inflammatory eosinophils (iEOS) in blood and lung samples from patients with allergic asthma. We explored if it would be possible to identify different subsets of eosinophils using flow cytometry and the gating strategy applied to induced sputum. We conducted an observational cross-sectional single-center study of 62 patients with persistent allergic asthma. Inflammatory cells from induced sputum samples were counted by light microscopy and flow cytometry, and cytokine levels in the supernatant were determined. Two subsets of eosinophils were defined that we call E1 (CD66b-high and CD15-high) and E2 (CD66b-low and CD15-low). Of the 62 patients, 24 were eosinophilic, 18 mixed, 10 paucigranulocytic, and 10 neutrophilic. E1 predominated over E2 in the eosinophilic and mixed patients (20.86% vs. 6.27% and 14.42% vs. 4.31%, respectively), while E1 and E2 were similar for neutrophilic and paucigranulocytic patients. E1 correlated with IL-5, fractional exhaled nitric oxide, and blood eosinophils. While eosinophil subsets have been identified for asthma in blood, we have shown that they can also be identified in induced sputum.
Diana Betancor, José María Olaguibel, José Manuel Rodrigo‐Muñoz, Ebymar Arismendi, Pilar Barranco, Blanca Barroso, Irina Bobolea, Blanca Cárdaba, María Jesús Cruz, Elena Curto,et al.
Wiley
Abstract Background and Aims Asthma is a heterogeneous respiratory disease that encompasses different inflammatory and functional endophenotypes. Many non‐invasive biomarkers has been investigated to its pathobiology. Heany et al proposed a clinical algorithm that classifies severe asthmatic patients into likely‐eosinophilic phenotypes, based on accessible biomarkers: PBE, current treatment, FeNO, presence of nasal polyps (NP) and age of onset. Materials and Methods We assessed the concordance between the algorithm proposed by Heany et al. with sputum examination, the gold standard, in 145 asthmatic patients of the MEGA cohort with varying grades of severity. Results No correlation was found between both classifications 0.025 (CI = 0.013–0.037). Moreover, no relationship was found between sputum eosinophilia and peripheral blood eosinophilia count in the total studied population. Discussion and Conclusion In conclusion, our results suggest that grouping the biomarkers proposed by Heany et al. are insufficient to diagnose eosinophilic phenotypes in asthmatic patients. Sputum analysis remains the gold standard to assess airway inflammation.
Alvar Agustí, Gaston De Stefano, Alberto Levi, Xavier Muñoz, Christian Romero-Mesones, Oriol Sibila, Alejandra Lopez-Giraldo, Vicente Plaza Moral, Elena Curto, Andrés L. Echazarreta,et al.
European Respiratory Society (ERS)
SARS-CoV-2 vaccines have been extremely effective in reducing the incidence of severe coronavirus disease 2019 (COVID-19) [1, 2], but effective and safe treatments for acute infection are still limited [3, 4]. An uncontrolled pulmonary inflammatory response to SARS-CoV-2 is considered a key pathogenic mechanism of COVID-19 progression [5], so systemic dexamethasone is recommended in severe cases [4, 6]. On the other hand, in very mild patients at home, inhaled corticosteroids (ICS) may prevent disease progression [7–10]. Whether ICS can also prevent disease progression in patients hospitalised because of COVID-19 has not been explored previously. Accordingly, we designed an investigator-initiated, open-label, randomised clinical trial (RCT) to explore the efficacy of adding inhaled budesonide to usual care to prevent disease progression in patients hospitalised because of COVID-19 pneumonia. We also carefully monitored the safety of this intervention since there are concerns about the use of systemic corticosteroids in other viral (influenza) lung infections [11]. The addition of inhaled budesonide to usual care is safe and may reduce the risk of disease progression in patients hospitalised because of COVID-19 pneumonia https://bit.ly/3tEQo3p
Leyre Baptista-Serna, José Manuel Rodrigo-Muñoz, Pablo Mínguez, Marcela Valverde-Monge, Ebymar Arismendi, Pilar Barranco, Blanca Barroso, Irina Bobolea, José Antonio Cañas, Blanca Cárdaba,et al.
Elsevier BV
Astrid Crespo-Lessmann, Sara Bernal, Elisabeth del Río, Ester Rojas, Carlos Martínez-Rivera, Nuria Marina, Abel Pallarés-Sanmartín, Silvia Pascual, Juan Luis García-Rivero, Alicia Padilla-Galo,et al.
Public Library of Science (PLoS)
Introduction Asthma with airway mucus hypersecretion is an inadequately characterized variant of asthma. While several studies have reported that hypersecreting patients may carry genetic variants in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, many of those studies have been questioned for their numerous limitations and contradictory results. Objectives (1) To determine the presence of genetic variants of the CFTR gene in patients with asthma with and without airway mucus hypersecretion. (2) To identify the clinical, inflammatory and functional characteristics of the asthma phenotype with airway mucus hypersecretion. Method Comparative multicentre cross-sectional descriptive study that included 100 patients with asthma (39 hypersecretors and 61 non-hypersecretors). Asthmatic hypersecretion was defined as the presence of cough productive of sputum on most days for at least 3 months in 2 successive years. The patients were tested for fractional exhaled nitric oxide, spirometry, induced sputum cell count, total immunoglobulin E (IgE), peripheral blood eosinophil count, C-reactive protein, blood fibrinogen and blood albumin and underwent a skin prick test. Asthma control and quality of life were assessed by the Asthma Control Test and Mini Asthma Quality of Life questionnaires, respectively. Blood DNA samples were collected from the patients and next-generation sequencing using a MiSeq sequencer and the Illumina platform was used for the CFTR gene analysis. Results Genetic differences were observed in the c.1680-870T>A polymorphism of the CFTR gene, significantly more evident in hypersecretors than in non-hypersecretors: 78.94% vs. 59.32% in the majority allele and 21.05% vs. 40.67% in the minority allele (p = 0.036). Clinically, asthma hypersecretors compared to non-hypersecretors were older (57.4 years vs. 49.4 years; p = 0.004); had greater asthma severity (58.9% vs. 23.7%; p = 0.005); experienced greater airway obstruction (FEV1/FVC% 64.3 vs. 69.5; p = 0.041); had poorer asthma control (60% vs. 29%; p = 0.021); had lower IgE levels (126.4 IU/mL vs. 407.6 IU/mL; p = 0.003); and were less likely to have a positive prick test (37.5% vs. 68.85%; p = 0.011). Conclusion The results suggest that patients with asthma and with mucus hypersecretion (1) may have a different phenotype and disease mechanism produced by an intronic polymorphism in the CFTR gene (NM_000492.3:c.1680-870T>A), and (2) may have a poorer clinical outcome characterized by severe disease and poorer asthma control with a non-allergic inflammatory phenotype.
Vicente Plaza, Carmen Fernández, Elena Curto, M. Belén Alonso-Ortiz, Miren Itxaso Orue, José María Vega, Borja G. Cosío, and Jordi Giner
Elsevier BV
Vicente Plaza, Carmen Fernández, Elena Curto, M. Bel,n Alonso-Ortiz, Miren Itxaso Orue, José María Vega, Borja G. Cosío, and Jordi Giner
Elsevier BV
Elena Curto, Alfons Torrego, Noe Garin, Astrid Crespo-Lessmann, and Vicente Plaza
Elsevier BV
V Plaza, , J Giner, E Curto, MB Alonso-Ortiz, MI Orue, JM Vega, and BG Cosío
Esmon Publicidad, SA
Background: The Global Initiative for Asthma (GINA) recommends the concurrent use of self-report and pharmacy refill data to assess treatment adherence. However, clinical evidence to support this combined approach is limited. Objective: To determine nonadherence to inhaler medication based on a validated questionnaire (Test of Adherence to Inhalers; TAI) and prescription refill data in a community sample of patients with chronic obstructive pulmonary disease (COPD) or asthma. Secondarily, we sought to determine the degree of concordance between these two measures. Methods: Cross-sectional, observational multicenter study in patients with asthma or COPD. Sociodemographic and clinical data were obtained from clinical records. Refill data were retrieved from electronic pharmacy databases. Participants completed the 12-item TAI during a single visit as part of routine care. Nonadherence was defined as TAI <50 or <80% pharmacy refill rate (PRR) in the previous 6 months. Results: A total of 816 patients (mean age, 60) were included. Nonadherence rates were 58.1% (TAI) and 28.6% (PRR) compared with 64.6% for the combined data (P<.0001). Concordance between the 2 measures was weak (к=0.205). Conclusions: These findings confirm the GINA recommendations, indicating that concomitant use of the TAI and pharmacy refill data identifies a higher percentage of nonadherent asthma or COPD patients than either instrument alone.
Manuel Jorge Rial, Marcela Valverde, Victoria del Pozo, Francisco Javier González-Barcala, Carlos Martínez-Rivera, Xavier Muñoz, José María Olaguibel, Vicente Plaza, Elena Curto, Santiago Quirce,et al.
Elsevier BV
Elena Curto, Alfons Torrego, Noe Garin, Astrid Crespo-Lessmann, and Vicente Plaza
Elsevier BV